Date: 2012-12-18
Type of information: R&D agreement
Compound: targeted peptide-drug conjugates (PDCs)
Company: Arrowhead (USA) Shire (UK)
Therapeutic area: Rare diseases
Type agreement: R&D
development
licensing
commercialisation
Action mechanism:
Disease: undisclosed
Details: Arrowhead Research Corporation, a targeted therapeutics company, has signed a research collaboration and license agreement with Shire, to develop and commercialize targeted peptide-drug conjugates (PDCs) by utilizing Arrowhead’s human-derived Homing Peptide platform and Shire’s therapeutic payloads. Arrowhead\'s library contains over 42,000 unique targeting peptide sequences can potentially be used to deliver therapeutics to more than 30 tissue types while avoiding non-specific uptake. Under the agreement, Arrowhead will identify peptides that selectively bind and internalize in an undisclosed tissue type and that are capable of delivering a therapeutic payload to that tissue. The company will receive funding for its internal and external research program-related costs and Shire will have an option to obtain an exclusive license to develop and commercialize a therapeutic agent targeted by the designated peptides and be responsible for clinical development and commercialization of products arising from the collaboration.
Financial terms: Arrowhead will receive research funding and could be eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales. Additional financial terms of the agreement were not disclosed.
Latest news:
